secwatch.observer — SEC 8-K summary
======================================

Issuer:     BridgeBio Oncology Therapeutics, Inc. (BBOT)
CIK:        0001869105
Form:       8-K
Filed at:   2025-11-12T23:59:59+00:00
Accession:  0001193125-25-277601
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BBOT Q3 2025 net loss $44.8M; cash $468.3M funds operations into 2028
---------------------------------------------------------------------

- Net loss of $44.8M vs $17.3M in Q3 2024; R&D expenses $35.1M, G&A $14.1M.
- Cash, equivalents and marketable securities $468.3M; runway expected into 2028.
- Closed SPAC business combination with Helix Acquisition Corp II on Aug 11, 2025; began trading on Nasdaq as BBOT.
- Appointed Uneek Mehra as CFO in July 2025.
- Three Phase 1 trials advancing (BBO-8520, BBO-10203, BBO-11818); initial clinical data readouts expected in 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1869105/000119312525277601/0001193125-25-277601-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1869105/000119312525277601/d814249d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-277601

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer